Your basket is currently empty!
Cabo + nivo & ipi delays kidney cancer progression
Adding cabozantinib (Cabometyx) to nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival ...
News Archive
Cabozantinib
Our work depends on donations from generous people so that we can support those affected by kidney cancer.
Would you like to support our work through a donation?
